{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-253174","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.625277+00:00","generated_at":"2026-05-30T03:43:27.270119+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arcellx Q3 net loss narrows; anito-cel hits 95% ORR in pivotal study with no neurotoxicity","bullets":["Q3 net loss $25.9M ($39.3M YoY); collaboration revenue $26M from Kite expansion.","Phase 2 iMMagine-1 (n=58): 95% ORR, 62% CR/sCR, median follow-up 10.3 months; 92% MRD negativity.","Phase 1 anito-cel: 30.2-month mPFS, median OS not reached at 38.1 months; 100% ORR.","No delayed neurotoxicity (parkinsonism, cranial nerve palsies) in >140 patients across trials.","Cash $676.7M funds into 2027; first patients dosed in iMMagine-3 with Kite manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-253174","json":"https://secwatch.observer/filing/0001193125-24-253174.json","markdown":"https://secwatch.observer/filing/0001193125-24-253174.md","text":"https://secwatch.observer/filing/0001193125-24-253174.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000119312524253174/0001193125-24-253174-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000119312524253174/d862473d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:43:27.270119+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}